# EDGAR Filing Document

**Accession Number:** 0001867496
**File Stem:** 0001493152-26-012763
**Filing Date:** 2026-3
**Character Count:** 17370
**Document Hash:** 8a7fe7c553384116492ef0f83d1adc2f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-012763.hdr.sgml**: 20260325

**ACCESSION NUMBER**: 0001493152-26-012763

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20260325

**DATE AS OF CHANGE**: 20260325

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CRYO CELL INTERNATIONAL INC
- **CENTRAL INDEX KEY:** 0000862692
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 223023093
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1130

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-80299
- **FILM NUMBER:** 26794166

**BUSINESS ADDRESS:**
- **STREET 1:** 700 BROOKER CREEK BLVD
- **STREET 2:** SUITE 1800
- **CITY:** OLDSMAR
- **STATE:** FL
- **ZIP:** 34677
- **BUSINESS PHONE:** 813-749-2104

**MAIL ADDRESS:**
- **STREET 1:** 700 BROOKER CREEK BLVD
- **STREET 2:** SUITE 1800
- **CITY:** OLDSMAR
- **STATE:** FL
- **ZIP:** 34677
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Camac Partners, LLC
- **CENTRAL INDEX KEY:** 0001867496

**ORGANIZATION NAME:**
- **EIN:** 275419503
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **STREET 1:** 350 PARK AVENUE
- **STREET 2:** 13TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** 9146298496

**MAIL ADDRESS:**
- **STREET 1:** 350 PARK AVENUE
- **STREET 2:** 13TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022

## Ex-1

**Exhibit 1**

SCHEDULE A

<u>Transactions in the Shares by the Reporting Persons During the Past 60 Days</u>

---

| | | |
|:---|:---|:---|
| Date of<br> Purchase | Shares of Common Stock<br> Purchased | Price Per<br> Share ($) |
| CAMAC FUND, LP | CAMAC FUND, LP | CAMAC FUND, LP |
| 1/26/2026 | 2099 | $3.409 |
| 1/27/2026 | 1802 | $3.405 |
| 1/28/2026 | 6346 | $3.410 |
| 1/29/2026 | 3263 | $3.386 |
| 1/30/2026 | 3478 | $3.410 |
| 2/2/2026 | 13577 | $3.377 |
| 2/3/2026 | 156 | $3.408 |
| 2/4/2026 | 300 | $3.397 |
| 2/5/2026 | 40539 | $3.400 |
| 2/6/2026 | 46632 | $3.403 |
| 2/9/2026 | 10388 | $3.372 |
| 2/10/2026 | 633 | $3.409 |
| 2/11/2026 | 7352 | $3.355 |
| 2/12/2026 | 8902 | $3.367 |
| 2/13/2026 | 17806 | $3.334 |
| 2/17/2026 | 780 | $3.390 |
| 2/18/2026 | 7168 | $3.341 |
| 2/19/2026 | 12396 | $3.331 |
| 2/20/2026 | 2000 | $3.360 |
| 2/23/2026 | 1700 | $3.370 |
| 2/24/2026 | 3679 | $3.402 |
| 2/25/2026 | 8 | $3.360 |
| 2/26/2026 | 1000 | $3.403 |
| 3/2/2026 | 1114 | $3.250 |
| 3/3/2026 | 8804 | $3.250 |
| 3/5/2026 | 3232 | $3.252 |
| 3/6/2026 | 8118 | $3.210 |
| 3/9/2026 | 8396 | $3.201 |
| 3/10/2026 | 2326 | $3.191 |
| 3/11/2026 | 4640 | $3.164 |
| 3/12/2026 | 7954 | $3.142 |
| 3/13/2026 | 25477 | $3.033 |
| 3/17/2026 | 14382 | $2.964 |
| 3/18/2026 | 30000 | $2.993 |
| 3/19/2026 | 3401 | $3.083 |
| 3/20/2026 | 18805 | $3.175 |
| 3/23/2026 | 19926 | $3.056 |
| 3/24/2026 | 10001 | $3.069 |
| 3/25/2026 | 8885 | $3.117 |

---

## Exhibit 99.1

**Exhibit 99.1**

**JOINT FILING AGREEMENT**

This JOINT FILING AGREEMENT is entered into as of March 25, 2026, by and among the signatories hereto. The undersigned hereby agree that the Statement on Schedule 13D with respect to the shares of Common Stock of Cryo-Cell International, Inc.., and any amendment thereafter signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities Exchange Act of 1934, as amended.

Dated: March 25, 2026

---

| | |
|:---|:---|
| **Camac Partners, LLC** | **Camac Partners, LLC** |
| By: Camac Capital, LLC, its general partner | By: Camac Capital, LLC, its general partner |
| By: | */s/ Eric Shahinian* |
| Eric Shahinian | Eric Shahinian |
| Managing Member of the GP | Managing Member of the GP |

---

---

| | |
|:---|:---|
| **Camac Capital, LLC** | **Camac Capital, LLC** |
| By: | */s/ Eric Shahinian* |
| Eric Shahinian | Eric Shahinian |
| Managing Member | Managing Member |

---

---

| | |
|:---|:---|
| By: | */s/ Eric Shahinian* |
| Eric Shahinian | Eric Shahinian |

---

---

| | |
|:---|:---|
| **Camac Fund, LP** | **Camac Fund, LP** |
| By: Camac Capital, LLC, its general partner | By: Camac Capital, LLC, its general partner |
| By: | */s/ Eric Shahinian* |
| Name: Eric Shahinian | Name: Eric Shahinian |
| Title: Managing Member of the GP | Title: Managing Member of the GP |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**Cryo-Cell International, Inc.**

*(Name of Issuer)*

**Common Stock**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**ERIC SHAHINIAN**<br>CAMAC PARTNERS, LLC<br>1601-1 N. MAIN STEET #3159, SMB#92283<br>JACKSONVILLE FL 32206<br>914-629-8496

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**03/23/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Camac Partners, LLC** | Name of reporting person<br>**Camac Partners, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**430900.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**430900.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**430900.00** | Aggregate amount beneficially owned by each reporting person<br>**430900.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.3%** | Percent of class represented by amount in Row (11)<br>**5.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Camac Capital, LLC** | Name of reporting person<br>**Camac Capital, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**430900.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**430900.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**430900.00** | Aggregate amount beneficially owned by each reporting person<br>**430900.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.3%** | Percent of class represented by amount in Row (11)<br>**5.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Camac Fund, LP** | Name of reporting person<br>**Camac Fund, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**430900.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**430900.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**430900.00** | Aggregate amount beneficially owned by each reporting person<br>**430900.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.3%** | Percent of class represented by amount in Row (11)<br>**5.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Eric Shahinian** | Name of reporting person<br>**Eric Shahinian** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**430900.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**430900.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**430900.00** | Aggregate amount beneficially owned by each reporting person<br>**430900.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.3%** | Percent of class represented by amount in Row (11)<br>**5.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock

**(b) Name of Issuer:**
Cryo-Cell International, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
700 Brooker Creek Blvd., Suite 1800, Oldsmar, FL, 34677

**Item 4. Purpose of Transaction**

The Reporting Persons purchased the securities of the Issuer reported herein based on the Reporting Persons' belief that such securities, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of securities of the Issuer at prices that would make the purchase or sale of such securities desirable, the Reporting Persons may endeavor to (i) increase or decrease their respective positions in the Issuer through, among other things, the purchase or sale of securities of the Issuer on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable and/or (ii) enter into transactions that increase or hedge their economic exposure to the securities of the Issuer without affecting their beneficial ownership of the Shares.

No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon completion of any of the actions discussed herein. The Reporting Persons intend to review their investments in the Issuer on a periodic basis and may from time to time engage in communications and discussions with management and the Board of Directors of the Issuer (the "Board"), other stockholders of the Issuer and third parties concerning, among other things, Board composition and corporate governance, levels of expenditures, monetization of all of the company's assets, and return of capital to shareholders.

The Reporting Persons may, at any time and from time to time, review or reconsider their position and/or change their purpose and/or formulate plans or proposals with respect thereto.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The aggregate percentage of shares of Common Stock reported owned by each person named herein is based upon 8,055,150 shares of Common Stock outstanding, which is the total number of shares of Common Stock reported outstanding as of the Issuer's Quarterly Report on Form 10-K, filed with the Securities and Exchange Commission for the period ended November 30, 2026.

As of the close of business on the date hereof, Camac Fund beneficially owned 430,900 shares of Common Stock.

Percentage: Approximately 5.3%

**(b)**
By virtue of their respective positions with Camac Fund, each of Camac Partners, Camac Capital, and Eric Shahinian may be deemed to have shared power to vote and dispose of the Shares reported owned by Camac Fund.

**(c)**
Schedule A annexed hereto lists all transactions in securities of the Issuer by the Reporting Persons during the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Exhibit 99.1 Joint Filing Agreement.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Camac Partners, LLC

**Signature:** /s/ Eric Shahinian

**Name/Title:** Eric Shahinian/Managing Member of the GP

**Date:** 03/25/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Camac Capital, LLC

**Signature:** /s/ Eric Shahinian

**Name/Title:** Eric Shahinian/Managing Member

**Date:** 03/25/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Camac Fund, LP

**Signature:** /s/ Eric Shahinian/general partner

**Name/Title:** Eric Shahinian/Managing Member of the GP

**Date:** 03/25/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Eric Shahinian

**Signature:** /s/ Eric Shahinian

**Name/Title:** Eric Shahinian

**Date:** 03/25/2026